Lantheus Stock Forecast
NASDAQ: LNTHHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
Market open · Delayed 15 min · as of Oct 8, 12:53 PM ET
LNTH analyst consensus
Consensus (10 analysts)
none
Avg. price target
$107.74+7.52%
- Strong buy 1
- Buy 2
- Hold 7
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 10 Wall Street analysts covering Lantheus (2026-10-07), 3 rate the stock a buy or strong buy, 7 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $107.74, with a high estimate of $115.00 and a low estimate of $102.50. The average target implies upside of 7.5% from the current price of $100.20.
The spread between the highest and lowest targets is 12.2%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for LNTH.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 10% |
| Buy | 2 | 20% |
| Hold | 7 | 70% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $102.50 | +2.30% |
| Average target | $107.74 | +7.52% |
| High target | $115.00 | +14.77% |